Prostate cancer: to screen or not to screen?

Area of Science:

• Oncology
• Public Health
• Urology

Background:

• Prostate cancer is a significant health burden, particularly in older men.
• The natural history of prostate cancer is poorly understood, leading to controversy over managing screen-detected lesions.
• Current screening methods (PSA, ultrasound, biopsy) have inadequate specificity and sensitivity.

Purpose of the Study:

• To evaluate the effectiveness of prostate cancer screening programs.
• To determine if early detection and treatment improve survival and quality of life.
• To address the controversy surrounding the management of screen-detected prostate cancers.

Main Methods:

• Review of current prostate cancer screening protocols, including serum prostate specific antigen (PSA) testing.
• Assessment of diagnostic accuracy of screening modalities (PSA, transrectal ultrasound, biopsy).
• Analysis of treatment options for localized prostate cancer: radical prostatectomy, radiotherapy, and active surveillance.

Main Results:

• No randomized controlled trial evidence currently demonstrates a survival advantage for radical prostatectomy, radiotherapy, or active surveillance.
• Existing screening methods lack sufficient specificity and sensitivity, leading to potential overdiagnosis and overtreatment.
• The benefits of radical treatments in improving survival and quality of life for screen-detected prostate cancer remain unclear.

Conclusions:

• The central question remains whether radical treatments for prostate cancer can truly improve survival and quality of life.
• Further research is needed to refine diagnostic testing, identify molecular markers for progression, and explore chemoprevention strategies.
• The benefit-harm balance of prostate cancer screening programs requires careful consideration, especially regarding survival and quality of life outcomes.